MXPA04000775A - Uso novedoso del 2 -[5-(4-fluorofenil) -3-piridilmetilamino-metil] -cromano y sus sales fisiologicamente aceptables. - Google Patents

Uso novedoso del 2 -[5-(4-fluorofenil) -3-piridilmetilamino-metil] -cromano y sus sales fisiologicamente aceptables.

Info

Publication number
MXPA04000775A
MXPA04000775A MXPA04000775A MXPA04000775A MXPA04000775A MX PA04000775 A MXPA04000775 A MX PA04000775A MX PA04000775 A MXPA04000775 A MX PA04000775A MX PA04000775 A MXPA04000775 A MX PA04000775A MX PA04000775 A MXPA04000775 A MX PA04000775A
Authority
MX
Mexico
Prior art keywords
pyridylmethylaminomethyl
chromane
fluorophenyl
physiologically acceptable
acceptable salts
Prior art date
Application number
MXPA04000775A
Other languages
English (en)
Spanish (es)
Inventor
Seyfried Christoph
Original Assignee
Merck Patent Ges Mit Baschrank
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Ges Mit Baschrank filed Critical Merck Patent Ges Mit Baschrank
Publication of MXPA04000775A publication Critical patent/MXPA04000775A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MXPA04000775A 2001-07-26 2002-07-10 Uso novedoso del 2 -[5-(4-fluorofenil) -3-piridilmetilamino-metil] -cromano y sus sales fisiologicamente aceptables. MXPA04000775A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01118097 2001-07-26
PCT/EP2002/007660 WO2003009835A2 (en) 2001-07-26 2002-07-10 Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts

Publications (1)

Publication Number Publication Date
MXPA04000775A true MXPA04000775A (es) 2004-04-20

Family

ID=8178137

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04000775A MXPA04000775A (es) 2001-07-26 2002-07-10 Uso novedoso del 2 -[5-(4-fluorofenil) -3-piridilmetilamino-metil] -cromano y sus sales fisiologicamente aceptables.

Country Status (23)

Country Link
US (1) US7872030B2 (https=)
EP (1) EP1408964B1 (https=)
JP (1) JP2004538289A (https=)
KR (1) KR20040029325A (https=)
CN (1) CN1292749C (https=)
AR (1) AR037496A1 (https=)
AT (1) ATE352302T1 (https=)
AU (1) AU2002355170B2 (https=)
BR (1) BR0211358A (https=)
CA (1) CA2455621C (https=)
CY (1) CY1107616T1 (https=)
DE (1) DE60217870T2 (https=)
DK (1) DK1408964T3 (https=)
ES (1) ES2280602T3 (https=)
HU (1) HUP0402092A3 (https=)
MX (1) MXPA04000775A (https=)
MY (1) MY134059A (https=)
PE (1) PE20030277A1 (https=)
PL (1) PL208258B1 (https=)
PT (1) PT1408964E (https=)
RU (1) RU2297833C2 (https=)
SI (1) SI1408964T1 (https=)
WO (1) WO2003009835A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR058439A1 (es) 2005-07-26 2008-02-06 Portela & Ca Sa Derivados de nitrocatecol como inhibidores de comt. procesos de obtencion y composiciones farmaceuticas.
PT2161038E (pt) 2006-01-26 2014-03-10 Isis Pharmaceuticals Inc Composições e suas utilizações dirigidas à huntingtina
EP1845097A1 (en) * 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
EP2481410B1 (en) 2007-01-31 2016-07-13 BIAL - Portela & Ca., S.A. Nitrocatechol derivates as COMT inhibitors administered with a specific dosage regime
KR20110002462A (ko) 2008-03-17 2011-01-07 바이알 - 포르텔라 앤드 씨에이 에스에이 5-[3-(2,5-디클로로-4,6-디메틸-1-옥시-피리딘-3-일)-[1,2,4]옥사디아졸-5-일]-3-나이트로벤젠-1,2-디올의 결정형
AU2010231961B2 (en) 2009-04-01 2015-05-21 Bial - Portela & Ca., S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
EP3626823A1 (en) * 2009-09-11 2020-03-25 Ionis Pharmaceuticals, Inc. Modulation of huntingtin expression
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
WO2013089573A1 (en) 2011-12-13 2013-06-20 BIAL - PORTELA & Cª., S.A. Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor
JP2018500300A (ja) 2014-11-28 2018-01-11 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US576132A (en) * 1897-02-02 Current water-wheel
DE2364685C3 (de) 1973-12-27 1978-06-15 Beiersdorf Ag, 2000 Hamburg Phenoxyäthylamine
US4438119A (en) * 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
CA1337429C (en) 1983-12-05 1995-10-24 Guy Rosalia Eugene Van Lommen Derivatives of 2,2'-iminobisethanol
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
DE3901814A1 (de) 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
EP0465254B1 (en) 1990-07-06 1996-11-13 Yoshitomi Pharmaceutical Industries, Ltd. Fused thiophene compounds and uses thereof
DE4135474A1 (de) 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
US5314888A (en) 1992-02-21 1994-05-24 Trustees Of Tufts College Veterinary method for treating inappropriate elimination of urine in household pets
SI9300097B (en) 1992-02-27 2001-12-31 Janssen Pharmaceutica Nv (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines
AU3929493A (en) 1992-03-11 1993-10-05 Interneuron Pharmaceuticals, Inc. Reducing post-prandial fluctuations in plasma concentrations of large neutral amino acids (lnaa)
DE4226527A1 (de) 1992-08-11 1994-02-17 Merck Patent Gmbh 1,4-Benzodioxanderivate
GB9302622D0 (en) 1993-02-10 1993-03-24 Wellcome Found Heteroaromatic compounds
CN1048247C (zh) * 1994-01-31 2000-01-12 美国辉瑞有限公司 神经保护的苯并二氢吡喃化合物
ZA954688B (en) 1994-06-08 1996-01-29 Lundbeck & Co As H Serotonin 5-HT1A and dopamin D2 receptor ligands
PT707007E (pt) * 1994-10-14 2002-06-28 Merck Patent Gmbh Derivados amino(tio)eter como agentes activos no snc
US5502080A (en) 1994-11-01 1996-03-26 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of allergic disorders
US5554383A (en) 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
US5541199A (en) 1995-06-02 1996-07-30 American Home Products Corporation Chroman-2-ylmethylamino derivatives
AU6517196A (en) 1995-07-13 1997-02-10 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
GB9514380D0 (en) 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
US5670667A (en) * 1995-07-25 1997-09-23 American Home Products Corporation Chroman-2-ylmethylamino derivatives
US5756521A (en) * 1996-04-03 1998-05-26 American Home Products Corporation Chroman-2-ylmethylamino derivatives
DE19648384A1 (de) 1996-11-22 1998-05-28 Merck Patent Gmbh Fluorene, Dibenzofurane und Dibenzothiophene
EP0900792B1 (en) 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists
DE69819266T2 (de) 1997-09-02 2004-07-29 Duphar International Research B.V. Piperidin- und Piperazin Derivate als 5-HT1-Rezeptor-Agonisten
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
US6242456B1 (en) 1998-03-09 2001-06-05 Trustees Of Tufts College Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
CN1155567C (zh) 1998-04-29 2004-06-30 惠氏公司 抑制精神的吲哚基衍生物
UA71590C2 (en) 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives
UA73981C2 (en) * 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit

Also Published As

Publication number Publication date
PL367291A1 (en) 2005-02-21
HUP0402092A2 (hu) 2005-02-28
RU2297833C2 (ru) 2007-04-27
AR037496A1 (es) 2004-11-17
AU2002355170B2 (en) 2007-06-07
DE60217870D1 (de) 2007-03-15
DE60217870T2 (de) 2007-11-15
CN1535150A (zh) 2004-10-06
ES2280602T3 (es) 2007-09-16
MY134059A (en) 2007-11-30
KR20040029325A (ko) 2004-04-06
SI1408964T1 (sl) 2007-06-30
PT1408964E (pt) 2007-05-31
CA2455621C (en) 2010-11-16
WO2003009835A3 (en) 2003-08-07
DK1408964T3 (da) 2007-05-21
WO2003009835A2 (en) 2003-02-06
CY1107616T1 (el) 2013-03-13
US20040171645A1 (en) 2004-09-02
RU2004105844A (ru) 2005-05-10
PL208258B1 (pl) 2011-04-29
PE20030277A1 (es) 2003-03-25
CN1292749C (zh) 2007-01-03
BR0211358A (pt) 2004-09-21
US7872030B2 (en) 2011-01-18
EP1408964B1 (en) 2007-01-24
JP2004538289A (ja) 2004-12-24
ATE352302T1 (de) 2007-02-15
HK1068793A1 (en) 2005-07-29
EP1408964A2 (en) 2004-04-21
HUP0402092A3 (en) 2010-06-28
CA2455621A1 (en) 2003-02-06

Similar Documents

Publication Publication Date Title
GB0117645D0 (en) Therapeutic stratergies for prevention and treatment of alzheimers disease
CY1107616T1 (el) Καινοτομος χρηση της 2-[5-(4-φθοροφαινυλο)-3-πυριδυλομεθυλαμινομεθυλο]-χρωμανης και των φυσιολογικα αποδεκτων αλατων της
GEP20053600B (en) 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors
GEP20074047B (en) Pramipexole once-daily dosage form
PL361341A1 (pl) Nowa kompozycja farmaceutyczna
SE9903760D0 (sv) New compounds
AP2004003124A0 (en) Thiazole and oxazole derivatives which modulate PPAR activity
MXPA05003253A (es) Nuevos derivados de pirimidinamida y el uso de los mismos.
SG162614A1 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
MXPA03000439A (es) Nueva forma de (r)-n-(5-metil -8-(4-metilpiperazin -1-il) -1,2,3,4-tetrahidro-2-naftil) -4-morfolinobenzamida.
EA200701181A1 (ru) Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний
MY136449A (en) N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide for the treatment of cancer
YU67402A (sh) Nova upotreba (r)-(-)-2-/5-(4-fluorofenil)-3- piridilmetilaminometil/-hromana i njegovih fiziološki prihvatljivih soli
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
MY128529A (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
HUP0402654A2 (hu) 2-[(2'-Halogén-3',5'-dialkoxi-fenil)-imino]-imidazolidin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
MXPA01009032A (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso se la produccion de il-12.
NO20010984D0 (no) Anvendelse av R(+)-<alfa>-(2,3-dimetoksyfenyl)-1-[2-(4- fluorfenyl)etyl]-4-piperidinmetanol for behandling av søvnforstyrrelser
MXPA04001001A (es) PRAMIPEXOL PARA EL TRATAMIENTO DEL TRASTORNO DE HIPERACTIVIDAD Y DeFICIT DE LA ATENCION.
ITMI20011185A0 (it) Protesi per l'occlusione dell'auricola cardiaca sinistra con impiantotranscatetere
YU17002A (sh) Upotreba deksrazoksana u lečenju psorijaze
ITTO20010526A0 (it) Vite implantare per protesi dentaria.
ITTO20010528A0 (it) Vite implantare per protesi dentaria.
AU2002229864A1 (en) Cysteine for oral administration for dry eye treatment

Legal Events

Date Code Title Description
FG Grant or registration